Tibor Csőszi

Researcher Next ID · RN-013913

Researcher · Medicine

, Hungary

Not currently recruitingFunding unknown

Research interests

Medicine

Biochemistry, Genetics and Molecular Biology

Advanced Breast Cancer Therapies

Cancer Immunotherapy and Biomarkers

Cancer Genomics and Diagnostics

Lung Cancer Treatments and Mutations

Cancer Treatment and Pharmacology

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
The Lancet · 2020 · 10.1016/s0140-6736(20)32531-9
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
The Lancet · 2019 · 10.1016/s0140-6736(19)32591-7
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Journal of Clinical Oncology · 2019 · 10.1200/jco.18.00149
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2018 · 10.1056/nejmoa1810865
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2016 · 10.1056/nejmoa1606774

No projects listed.